Ophthalmic formulation of vascular endothelial growth factor antagonist, a method of producing the same and syringe suitable for intravitreal administration comprising the same
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence showing in SEQ ID No: 4 or amino acids 27-457 of SEQ ID No: 4.
